Literature DB >> 31464711

Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases.

Eric D Carlsen1, Steven H Swerdlow1, James R Cook2, Sarah E Gibson1.   

Abstract

Primary cutaneous marginal zone lymphoma (PCMZL) can be subdivided into 2 groups based on immunoglobulin (Ig) heavy chain usage: IgM-positive cases that constitute a less common and more T-helper type 1-driven process, and more common heavy chain class-switched cases that are predominantly T-helper type 2-driven. Although some report a significant IgG4-positive subset, others have found a much smaller proportion. To further evaluate the proportion of IgG4-positive PCMZL, to address whether IgG4-positive cases have any distinctive characteristics, and to assess whether additional features separating IgM-positive and class-switched cases could be identified, the clinicopathologic features of 26 PCMZL obtained from 19 patients were investigated. Twenty of 26 (77%) PCMZL were heavy chain class-switched (19 IgG-positive, 1 IgA-positive), including 9 that were IgG4-positive (35%). IgG4-positive and other class-switched PCMZL were morphologically similar. IgM-positive cases occurred in older individuals (median: 69 vs. 46.5 y; P=0.0001), more often involved the subcutis (P=0.002), demonstrated plasma cells diffusely scattered versus at the periphery of the lymphoid infiltrate (P=0.005), uniformly showed follicular colonization (P=0.0001), contained more numerous B cells (P=0.0004), and were more likely to have a T-cell CD4:CD8 ratio of <3:1 (P=0.03). None of the IgM-positive PCMZL harbored a MYD88 L265P mutation. No significant differences in clinical outcome were documented. These results highlight the high frequency of IgG4-positive PCMZL, which are otherwise similar to other class-switched cases, provide additional evidence supporting the distinction between class-switched and IgM-positive cases, and emphasize the indolent nature of at least the class-switched PCMZL, which may warrant their categorization as a clonal chronic lymphoproliferative disorder.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31464711     DOI: 10.1097/PAS.0000000000001363

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

Review 1.  Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas.

Authors:  Amanda Krenitsky; Skylar Klager; Leigh Hatch; Carlos Sarriera-Lazaro; Pei Ling Chen; Lucia Seminario-Vidal
Journal:  Am J Clin Dermatol       Date:  2022-07-19       Impact factor: 6.233

Review 2.  Recent advances in cutaneous lymphoma-implications for current and future classifications.

Authors:  J R Goodlad; L Cerroni; S H Swerdlow
Journal:  Virchows Arch       Date:  2022-10-24       Impact factor: 4.535

3.  Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling.

Authors:  Audrey Gros; Sarah Menguy; Victor Bobée; Océane Ducharme; Isabelle Cirilo Cassaigne; Béatrice Vergier; Marie Parrens; Marie Beylot-Barry; Anne Pham-Ledard; Philippe Ruminy; Fabrice Jardin; Jean-Philippe Merlio
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.752

Review 4.  Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas.

Authors:  Andrea Ronchi; Antonello Sica; Paola Vitiello; Renato Franco
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-03-08

5.  Deep Sequencing of Immunoglobulin Genes Identifies a Very Low Percentage of Monoclonal B Cells in Primary Cutaneous Marginal Zone Lymphomas with CD30-Positive Hodgkin/Reed-Sternberg-like Cells.

Authors:  Arianna Di Napoli; Evelina Rogges; Niccolò Noccioli; Anna Gazzola; Gianluca Lopez; Severino Persechino; Rita Mancini; Elena Sabattini
Journal:  Diagnostics (Basel)       Date:  2022-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.